Tomas Hode

Founder at Immunophotonics, Inc.

Health Technology

Consumer Services

Profile

Tomas Hode is the founder of Immunophotonics, Inc., a company founded in 2009, where he currently holds the title of President, Chief Innovation Officer & Director.
He is also currently working as the Director at the Missouri Biotechnology Association.
Dr. Hode obtained his doctorate degree from the University of Stockholm in 2005.

Tomas Hode active positions

Companies	Position	Start
Immunophotonics, Inc. Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.	Founder	2008-12-31
Missouri Biotechnology Association	Director/Board Member	-

All active positions of Tomas Hode

Training of Tomas Hode

University of Stockholm

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Tomas Hode's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Immunophotonics, Inc. Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.	Health Technology
Missouri Biotechnology Association